Study of the Activity of 3-benzyl-5-(4-chloro-arylazo)‎-4-thioxo-imidazolidin-2-one against Schistosomiasis Mansoni in Mice

Abstract EN

Previous studies conducted with the imidazolidinic derivative 3-benzyl-5-(4-chloro-arylazo)-4-thioxo-imidazolidin-2-one (LPSF-PT05) show outstanding activity against adult Schistosoma mansoni worms in vitro.

In the first phase of this study, S.

mansoni-infected mice were treated, orally, with 100 mg/Kg of the LPSF-PT05 in three formulations: Tween 80 and saline solution, oil/water (70 : 30) emulsion, and solid dispersion with polyethylene glycol (PEG).

In the second phase, three other doses of the LPSF-PT05 in PEG were tested: 3, 10, 30 mg/kg.

These treatment regimens significantly reduced the number of recovered worms due to increases in the solubility of the compound in this formulation; the greatest reduction (70.5%) was observed at the dose of 100 mg/kg.

There was no changes in the pattern of mature egg compared to immature eggs; however there was a significant increase in the number of dead eggs.

Histopathological analysis of liver tissue showed changes in morphological aspects of the hepatic parenchyma with decrease exudative-productive hepatic granuloma stages, although we found no significant differences in IFN-γ, IL-4, IL-10, or NO production in response to the specific antigen SEA.

The results show the derivative LPSF-PT05 to be a potential candidate in the etiological treatment of schistosomiasis with a possible dampening effect of the granulomatous process.